{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:39Z","timestamp":1791489579588,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":235,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101411","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:44:06Z","timestamp":1787705046000},"page":"101411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6846-187X","authenticated-orcid":false,"given":"Minehiko","family":"Inomata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Moriyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4095-4533","authenticated-orcid":false,"given":"Yuichi","family":"Tambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-9558","authenticated-orcid":false,"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101411_bib0001","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101411_bib0002","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus Pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101411_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/dbio.1999.9234","article-title":"Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-\/-) mouse embryos","volume":"209","author":"Minoo","year":"1999","journal-title":"Dev. Biol."},{"key":"10.1016\/j.ctarc.2026.101411_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/ajcp\/aqy083","article-title":"Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases","volume":"150","author":"Vidarsdottir","year":"2018","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ctarc.2026.101411_bib0005","article-title":"Impact of TTF-1 expression on the prognostic prediction of patients with NSCLC with PD-L1 expression levels of 1% to 49%, treated with chemotherapy vs chemoimmunotherapy: a multicenter, retrospective study","author":"Nishioka","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101411_bib0006","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.10-3149","article-title":"Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment","volume":"141","author":"Chung","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ctarc.2026.101411_bib0007","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.21037\/tlcr-22-393","article-title":"Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1\/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer","volume":"11","author":"Ibusuki","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101411_bib0008","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/1759-7714.14560","article-title":"Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma","volume":"13","author":"Nakahama","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.ctarc.2026.101411_bib0009","article-title":"TTF-1 expression and clinical outcomes of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma: a prospective observational study","volume":"4","author":"Katayama","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.ctarc.2026.101411_bib0010","article-title":"Predictive impact of diffuse positivity for TTF-1 expression in patients treated with Platinum-doublet chemotherapy plus immune checkpoint inhibitors for advanced nonsquamous NSCLC","volume":"4","author":"Terashima","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.ctarc.2026.101411_bib0011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00432-024-05916-x","article-title":"Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-\/immunotherapy in patients with non-small cell lung cancer","volume":"150","author":"Uhlenbruch","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101411_bib0012","first-page":"11","article-title":"TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapy","volume":"24","author":"Murayama","year":"2026","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101411_bib0013","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.cllc.2020.05.014","article-title":"Pemetrexed-based chemotherapy is inferior to Pemetrexed-free regimens in thyroid transcription factor 1 (TTF-1)-negative, EGFR\/ALK-negative lung adenocarcinoma: A propensity score matched pairs analysis","volume":"21","author":"Frost","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101411_bib0014","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.21037\/tlcr-23-331","article-title":"Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer","volume":"12","author":"Iso","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101411_bib0015","article-title":"Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001)","volume":"17","author":"Inomata","year":"2026","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ctarc.2026.101411_bib0016","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/emboj.2011.416","article-title":"MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis","volume":"31","author":"Hosono","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.ctarc.2026.101411_bib0017","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1111\/cas.13313","article-title":"Inactivating mutations and hypermethylation of the NKX2-1\/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas","volume":"108","author":"Matsubara","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ctarc.2026.101411_bib0018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2013.02.018","article-title":"Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma","volume":"50","author":"Snyder","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ctarc.2026.101411_bib0019","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s13577-025-01275-y","article-title":"The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinoma","volume":"38","author":"Yamada","year":"2025","journal-title":"Hum. Cell"},{"key":"10.1016\/j.ctarc.2026.101411_bib0020","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-11-0407","article-title":"CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans","volume":"17","author":"Huang","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101411_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12335","article-title":"Interdependent IL-7 and IFN-\u03b3 signalling in T-cell controls tumour eradication by combined \u03b1-CTLA-4+\u03b1-PD-1 therapy","volume":"7","author":"Shi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101411_bib0022","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101411_bib0023","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418985122","article-title":"Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1","volume":"122","author":"Mok","year":"2025","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:36:40Z","timestamp":1791488200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"alternative-id":["S2468294226003217"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101411","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101411"}}